The increase in pro-inflammatory mediators in COVID-19 and in leprosy may increase the activity of the enzyme Indoleamine 2,3-dioxygenase 1 (IDO1), which results in the production of kynurenine metabolites (Belladonna and Orabona, 2020; Turski et al., 2020). Here, IDO1 is linked to leprosy.